Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Capacity for higher volumes is not booked revenue; Cosmos Health intends to fill it through organic growth and acquisitions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (COSM) reported record second-quarter 2026 revenue above $15 million at its CosmoFarm pharmacy distribution subsidiary.
That represents an annualized revenue run rate above $60 million, approximately 4.3 times CosmoFarm’s fiscal 2017 sales of approximately $14 million before its acquisition. The dollar-based growth figures reflect exchange-rate changes. Daily-served pharmacies rose from approximately 100 in 2017 to approximately 360 today. A signed 2026 letter of intent covers a network generating approximately €10 million (approximately $11.5 million) in annual gross revenue; a definitive agreement and closing conditions remain pending.
Cosmos Health expects expansion and automation to support $40 million or more in additional annual revenue capacity, potentially allowing CosmoFarm to operate above $100 million in annualized revenue if volume grows. The subsidiary is expected to contribute to Cosmos Health’s 2029 revenue target of $200.6 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointSecond-quarter 2026 revenue exceeded $15 million, a CosmoFarm record.
- Moderate pointAnnualized revenue exceeded $60 million, approximately 4.3 times fiscal 2017 sales of approximately $14 million.
- Moderate point2025 active customers grew approximately 20%.
- Moderate point2026 letter of intent covers a network generating approximately €10 million (approximately $11.5 million) in annual gross revenue.
- Moderate point. Forward-looking: it has not happened yet and may not happen.$40 million or more in additional annual revenue capacity could come from facility expansion and robotics.
- Moderate point. Forward-looking: it has not happened yet and may not happen.2029 revenue guidance targets $200.6 million.
- Moderate point€700,000 and €1.5 million bond-loan tranches provided financing in January 2025.
6 minor points
- Minor pointDaily-served pharmacies rose from approximately 100 in 2017 to approximately 360 today.
- Minor pointMore than 80 pharmacies joined the network in second-quarter 2026, following nearly 100 organic additions in 2025.
- Minor point2025 revenue per customer increased approximately 12%, while profitability per customer improved approximately 14%.
- Minor point. Forward-looking: it has not happened yet and may not happen.2029 gross profit guidance targets $71.2 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.2029 adjusted EBITDA guidance targets $44.2 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.2029 net income guidance targets $31.0 million.
Negative
- Moderate point2026 network acquisition remains at the letter-of-intent stage, subject to a definitive agreement and closing conditions.
- Moderate pointSeveral million euros have been invested in robotics and specialist personnel, with the program ongoing.
- Minor point. Forward-looking: it has not happened yet and may not happen.$40 million or more in potential additional capacity requires further customer volume to be used.
- Minor pointJanuary 2030 bond-loan maturity leaves debt secured on CosmoFarm’s distribution center.
News Explained
CosmoFarm’s building is already pledged as security for a European bank bond loan—described as non-dilutive liquidity—issued in
Details
Market move: COSM +8.10% vs previous close. CosmoFarm revenue update
On Sep 29, the day this news came out, the latest delayed price for COSM is 8.10% above the previous close. Our momentum scanner has recorded 20 alerts for this stock so far that day. The latest delayed price is $0.40. Relative volume is very high at 3.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Q2 2026 revenue
- Over $15 million
- CosmoFarm, second quarter 2026
- Annualized revenue run-rate
- Over $60 million
- Based on Q2 2026 revenue
- Revenue growth under Cosmos Health ownership
- Approximately 4.3x
- Compared with fiscal 2017 sales
- Daily-served pharmacies
- Approximately 360
- CosmoFarm's core daily-served customer base
- Acquisition candidate annual gross revenue
- Approximately $11.5 million
- Letter of intent; subject to definitive agreement and customary closing conditions
- Additional annual revenue capacity
- $40 million or more
- Potential facility and robotic capacity
- Annualized revenue capacity
- Above $100 million
- Company-stated potential with expanded capacity
- Revenue guidance
- $200.6 million
- 2029 company target
Previous AI Reports
-
Reported record Q2 revenue and expanded AI robotics and facility capacity
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
good distribution practices regulatory
compound annual growth rate financial
letter of intent financial
otc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / September 29, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. ("CosmoFarm"), which delivered record revenue of over
A Leading Pharmaceutical Distribution Platform
CosmoFarm is a fully licensed pharmaceutical wholesaler supplying pharmacies from its own distribution center in Peristeri, western Athens. Authorized by the National Organization for Medicines under Good Distribution Practices, it has built more than three decades of uninterrupted presence in the sector.
Its founding objective - structured, rapid service and accurate distribution - remains the operating standard. The range has since broadened to cover the full set of products pharmacies sell today, supported by sustained investment in robotics, automation and the systems that manage procurement, inventory and order execution.
| CosmoFarm at a glance | |
| Business | Wholesale supply and distribution to retail pharmacies |
| Regulatory status | Fully licensed wholesaler, authorized by the National Organization for Medicines under Good Distribution Practices |
| Product range | The full range of products sold by pharmacies, including branded and generic prescription medicines, over-the-counter medicines, parapharmaceuticals, cosmetics, dietary supplements, orthopedic products, medical devices, and infant nutrition and hygiene products |
| Product codes | Over 32,000 |
| Customers | More than 1,500 pharmacies, of which approximately 360 are served daily |
| Facility | Wholly owned 29,100-square-foot distribution center in Peristeri, western Athens |
| Automation and AI | ROWA and SSI SCHÄFER A-frame robotic systems for automated procurement, inventory management and order execution, with artificial intelligence being deployed across procurement, inventory and customer operations |
Quality, immediate and safe customer service is the division's stated priority, alongside a commitment to responsible use of resources and the recycling of paper and plastic across its operations.
Two Drivers of Growth: More Daily Customers, Each Worth More
CosmoFarm measures its customer base on two levels. Its total network comprises more than 1,500 pharmacies, up from over 1,130 at acquisition. Within it sits a core served on a daily basis - those for which CosmoFarm is a principal supplier rather than an occasional one. That core has grown from approximately 100 pharmacies in 2017 to approximately 360 today.
Converting a pharmacy from occasional to daily supply is the central commercial objective in pharmaceutical wholesale, where pharmacies typically source from several distributors. It demands service levels, availability and delivery reliability that smaller operators struggle to match, and it is the basis on which CosmoFarm has built its position.
Revenue has grown in step. In fiscal 2017, the last full year before Cosmos Health acquired the business, CosmoFarm recorded sales of approximately
The two effects compound. Daily-served pharmacies increased approximately 3.6 times, while average revenue per daily-served pharmacy rose by approximately
Growth has come from both organic customer wins and bolt-on transactions. During 2025 alone CosmoFarm added nearly 100 new pharmacy customers organically, with more than 80 further pharmacies added in the second quarter of 2026. Alongside this, three bolt-on acquisitions since 2019 have supported that growth, bringing established regional networks onto the platform.
Consolidating a Fragmented Market
Pharmaceutical wholesale in Greece remains fragmented across regional operators, many without the scale to invest in automation. Since 2019 CosmoFarm has pursued a consolidation strategy alongside organic growth: acquiring established regional networks and integrating their customers onto a single automated platform.
| YEAR | TRANSACTION | STRATEGIC SIGNIFICANCE |
| 2019 | PHARMASYN network | First transaction under the consolidation strategy, deepening the Attica customer base |
| 2023 | Bikas network | Integrated from July 2023, broadening distribution of branded and generic medicines, OTC products, supplements and medical devices |
| 2024 | Pelofarm network | First expansion beyond Attica - more than 30 pharmacies in Arcadia and the central Peloponnese, expected to add over |
| 2026 | Letter of intent signed | A network generating approximately €10 million (approximately |
The Pelofarm transaction extended the platform beyond Attica for the first time, establishing that the model is transferable to other regions. A further network acquisition is at the letter of intent stage and would be the largest to date. If completed, the Company expects it to accelerate growth significantly.
Operating Leverage
Network density is a principal driver of economics in pharmaceutical wholesale. Each additional pharmacy on an established route is expected to carry limited incremental cost, so customer growth can support improved margins where the infrastructure can absorb the volume.
During 2025, annual revenue per customer increased by approximately
Customer numbers, revenue per customer and profitability per customer rising together is consistent with operating leverage rather than volume growth alone.
Wholly Owned Real Estate Supporting Operations and Liquidity
CosmoFarm operates from a wholly owned 29,100-square-foot distribution center in Peristeri, a densely populated municipality in western Athens with established infrastructure and transport links. The facility houses the division's robotic and automation systems and forms part of the Company's wider real estate portfolio, which, taken as a whole, has been independently valued at approximately
The property has also served as a source of non-dilutive liquidity. In January 2025 the Company secured a bond loan from a European bank on very competitive terms, issued in two tranches of €700,000 and €1,500,000, secured on the CosmoFarm building and maturing in January 2030. Management believes the transaction underscores the strength and flexibility of the Company's real estate assets as an additional financing tool.
Capacity to Support Annualized Revenue Above
CosmoFarm has invested several million euros in robotic systems and specialist personnel, and that program is ongoing. The Company is adding further automation and artificial intelligence across procurement, inventory and order fulfillment, and expanding the facility for higher volumes. In June 2026 the Company also signed an agreement to deploy an AI-powered call center supporting multilingual voice, outbound campaigns and real-time reporting.
Facility expansion and robotic capacity could support an additional
Additional volume, whether organic or acquired, is expected to be absorbed at incremental cost, which is the principal mechanism through which the division's margins are expected to improve. Additional capacity reflects the Company's expectation regarding the volume the facility is able to process. The Company intends to utilize that capacity through continued organic growth and acquisitions.
Expected Contribution to 2029 Guidance
Cosmos Health has issued guidance targeting revenue of
CosmoFarm also strengthens Cosmos Health's vertically integrated model in its domestic market. The same network that distributes third-party pharmaceuticals and parapharmaceuticals carries the Company's proprietary brands, including Sky Premium Life and C-Scrub, giving those higher-margin products direct access to the pharmacy channel and allowing the Company to capture margin across manufacturing, distribution and brand ownership.
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated: "When we acquired CosmoFarm, it supplied around 100 pharmacies a day. Today it supplies around 360 a day, within a network of more than 1,500, and operates at more than four times the revenue. We got here by winning pharmacies one by one and by acquiring the right regional networks in a market that is still highly fragmented, and the letter of intent we signed this year would be our largest acquisition yet.
"What excites me most is the economics. Every pharmacy we add to an established route makes the whole network more profitable, and the robotics and AI we are deploying give us room to operate above
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did Cosmos Health’s CosmoFarm generate in the second quarter of 2026?
CosmoFarm generated more than $15 million in second-quarter 2026 revenue, a record for the subsidiary. That represents an annualized revenue run rate above $60 million, rather than revenue already earned over a full year.
What is the status of Cosmos Health’s 2026 CosmoFarm network acquisition?
Cosmos Health has signed a letter of intent for the network, which generates approximately €10 million (approximately $11.5 million) in annual gross revenue. The acquisition remains subject to a definitive agreement and closing conditions.
What are the terms of Cosmos Health’s loan secured on the CosmoFarm building?
The bond loan was issued in two tranches of €700,000 and €1.5 million, secured on the CosmoFarm building, and matures in January 2030. Cosmos Health secured it from a European bank in January 2025.